It is important to carefully examine studies of the relative ability of these two drugs in these two groups of patients with schizophrenia, since definitions and degrees of neuroleptic resistance may vary widely (7) and the psychotic symptoms of neuroleptic-intolerant patients may be equally responsive to the antipsychotic effects of the antipsychotic agents under study, while they may differ markedly in their effectiveness for neuroleptic-resistant patients. Thus, the fact that Dr. Bondolfi et al. (1) included both neuroleptic-resistant and neuroleptic-intolerant patients in their study is a potential confound. Data on the response of neuroleptic-resistant patients should have been reported separately but were not. Even had they been, the overall group size was small and probably lacked sufficient power to find a difference between the two drugs for either or both subgroups. Second, the determination of neuroleptic resistance included in this study was made retrospectively and included trials of only 4 weeks’ duration—too brief a period. A third concern is the rapid titration schedule for clozapine and the low final dose (300 mg/day) achieved, both of which should decrease its efficacy. The method of use and dose of risperidone (2–6 mg/day) may have been optimal. The low dose of risperidone no doubt contributed to the finding that motor side effects were less with risperidone than with clozapine. Fourth, the duration of the study may have been too short to find a difference between the two drugs. Clozapine has been shown to require up to 6 months to achieve its full benefits (8, 9). And finally, it is important to note the difficulty of maintaining a blind study with clozapine and risperidone because of their differences in side effects.